Defining the Right Dose Without Individualisation: Can Clinical Pharmacology & Dosimetry Deliver More Predictable Radioligand Therapy Outcomes?

1:30 pm - Wednesday 2nd December 2026

  • Reviewing the dose selection strategies underpinning currently approved radioligand therapies and evaluating what these programmes have taught us about efficacy, safety and treatment optimisation
  • Exploring how developers can use clinical pharmacology and dosimetry data to establish robust dose strategies across diverse patient populations
  • Understanding the trade-offs between personalised treatment approaches and operationally scalable dosing paradigms

Speakers:

VIce President, Global Head PK Sciences - Oncology
Novartis AG